Skip to main content

Advertisement

SpringerLink
Log in

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The clinical efficacy and safety of a four-drug combination of bortezomib, cyclophosphamide, thalidomide, and dexamethasone was assessed for patients with relapsed or refractory multiple myeloma. Seventy patients received at least two cycles of treatment with bortezomib 1.3 mg/m2 intravenously on days 1, 4, 8, and 11; cyclophosphamide 150 mg/m2 orally on days 1–4; thalidomide 50 mg/day orally every day; and dexamethasone 20 mg/m2 intravenously on days 1, 4, 8, and 11. The overall best response rate was 88%, with 46% complete response, 9% very good partial response, and 33% partial response. After a median follow-up of 12.6 months, the median progression-free survival (PFS) was 14.6 months with a 3-year PFS of 14% and the median overall survival (OS) was 31.6 months with a 3-year OS of 47%. Grade 3 or 4 adverse events included thrombocytopenia (12%), neutropenia (4%), peripheral sensory neuropathy (3%), with thrombosis being very rare (<1%). Bortezomib combined with cyclophosphamide, thalidomide, and dexamethasone is a highly effective salvage therapy with manageable toxicity for patients with relapsed or refractory multiple myeloma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351:1860–1873

    Article  CAS  PubMed  Google Scholar 

  2. Galton DA, Peto R (1968) A progress report on the Medical Research Council's therapeutic trial in myelomatosis. Br J Haematol 15:319–320

    Article  CAS  PubMed  Google Scholar 

  3. Sirohi B, Powles R (2004) Multiple myeloma. Lancet 363:875–887

    Article  PubMed  Google Scholar 

  4. Alexanian R, Barlogie B, Tucker S (1990) VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 33:86–89

    Article  CAS  PubMed  Google Scholar 

  5. Barlogie B, Jagannath S, Desikan KR et al (1999) Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93:55–65

    CAS  PubMed  Google Scholar 

  6. Samson D, Gaminara E, Newland A et al (1989) Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 2:882–885

    Article  CAS  PubMed  Google Scholar 

  7. Sirohi B, Powles R, Mehta J et al (1999) Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system. Br J Haematol 107:656–666

    Article  CAS  PubMed  Google Scholar 

  8. Goldschmidt H, Hegenbart U, Wallmeier M et al (1997) Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony stimulating factor in patients with multiple myeloma. Br J Haematol 98:736–744

    Article  CAS  PubMed  Google Scholar 

  9. Richardson PG, Hideshima T, Mitsiades C et al (2007) The emerging role of novel therapies for the treatment of relapsed myeloma. J Natl Compr Canc Netw 5:149–162

    CAS  PubMed  Google Scholar 

  10. San Miguel JF, Schlag R, Khuageva NK et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906–917

    Article  CAS  PubMed  Google Scholar 

  11. Dimopoulos M, Spencer A, Attal M et al (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123–2132

    Article  CAS  PubMed  Google Scholar 

  12. Weber DM, Chen C, Niesvizky R et al (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133–2142

    Article  CAS  PubMed  Google Scholar 

  13. Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609–2617

    Article  CAS  PubMed  Google Scholar 

  14. Jagannath S, Barlogie B, Berenson J (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127:165–172

    Article  CAS  PubMed  Google Scholar 

  15. Richardson PG, Sonneveld P, Schuster M et al (2007) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110:3557–3560

    Article  CAS  PubMed  Google Scholar 

  16. Wang LM, Weber DM, Delasalle KB et al (2004) VTD (Velcade, thalidomide, dexamethasone) as primary therapy for newly diagnosed multiple myeloma. Blood 104:210a

    Google Scholar 

  17. Oakervee HE, Popat R, Curry N et al (2005) PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 129:755–762

    Article  CAS  PubMed  Google Scholar 

  18. Dimopoulos MA, Zervas K, Kouvatseas G et al (2001) Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12:991–995

    Article  CAS  PubMed  Google Scholar 

  19. Weber DM, Rankin K, Gavino M et al (2000) Thalidomide with dexamethasone for resistant multiple myeloma. Blood 96:167a

    Google Scholar 

  20. Palumbo A, Giaccone L, Bertola A et al (2001) Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 86:399–403

    CAS  PubMed  Google Scholar 

  21. Garcia-Sanz R, Gonzalez-Fraile MI, Sierra M, Lopez C et al (2003) The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma. Hematol J 3:43–48

    Article  Google Scholar 

  22. Srkalovic G, Elson P, Trebisky B et al (2002) Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. Med Oncol 19:219–226

    Article  CAS  PubMed  Google Scholar 

  23. Richardson PG, Briemberg H, Jagannath S et al (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113–3120

    Article  CAS  PubMed  Google Scholar 

  24. Durie BG, Harousseau JL, Miguel JS et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467–1473

    Article  CAS  PubMed  Google Scholar 

  25. Chanan-Khan A, Sonneveld P, Schuster MW et al (2008) Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 26:4784–4790

    Article  CAS  PubMed  Google Scholar 

  26. Terpos E, Kastritis E, Roussou M et al (2008) The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 22:2247–2256

    Article  CAS  PubMed  Google Scholar 

  27. Palumbo A, Ambrosini MT, Benevolo G et al (2007) Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 109:2767–2772

    CAS  PubMed  Google Scholar 

  28. Musto P, Falcone A, Sanpaolo G et al (2006) Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. Leuk Res 30:283–285

    Article  CAS  PubMed  Google Scholar 

  29. Popat R, Oakervee H, Williams C et al (2009) Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. Br J Haematol 144:887–894

    Article  CAS  PubMed  Google Scholar 

  30. Reece DE, Rodriguez GP, Chen C et al (2008) Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 26:4777–4783

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Dr. Paul Richardson, Dana-Faber Cancer Institute, for critically review the manuscript.

Author information

Authors and Affiliations

  1. Chonnam National University Medical School, Gwangju, Republic of Korea

    Yeo-Kyeoung Kim, Deok-Hwan Yang, Jae-Sook Ahn, Hyeoung-Joon Kim & Je-Jung Lee

  2. Kyungpook National University Medical School, Daegu, Republic of Korea

    Sang-Kyun Sohn & Joon-Ho Moon

  3. Gachon University, Incheon, Republic of Korea

    Jae-Hoon Lee

  4. The Brain Korea 21 Project, Center for Biomedical Human Resources at Chonnam National University, Gwangju, Republic of Korea

    Je-Jung Lee

  5. Department of Hematology–Oncology, Chonnam National University Hwasun Hospital, 160, Ilsim-ri, Hwasun-eup, Hwasun-gun, Jeollanam-do, 519-809, Republic of Korea

    Je-Jung Lee

Authors
  1. Yeo-Kyeoung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sang-Kyun Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jae-Hoon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Deok-Hwan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joon-Ho Moon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jae-Sook Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hyeoung-Joon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Je-Jung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

The Korean Multiple Myeloma Working Party (KMMWP)

Corresponding author

Correspondence to Je-Jung Lee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, YK., Sohn, SK., Lee, JH. et al. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. Ann Hematol 89, 475–482 (2010). https://doi.org/10.1007/s00277-009-0856-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-009-0856-x

Keywords

Search

Navigation